Buy Ketorolac

Ketorolac

Ketorolac: Generic Medication Overview

Ketorolac contains Ketorolac Trometamol as its active component. It belongs to the non-steroidal anti-inflammatory drug (NSAID) class and is used for short-term management of moderate to severe pain. In Hong Kong, Ketorolac is available only by prescription (Rx) and is supplied as a 10 mg oral tablet (pill).

How Ketorolac Works in the Body

Ketorolac inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which are essential for converting arachidonic acid into prostaglandins. Prostaglandins amplify pain signals, promote inflammation, and sensitize nerve endings. By blocking COX activity, Ketorolac reduces the production of these prostaglandins, leading to:

• Decreased pain perception
• Reduced inflammation and swelling
• Lowered fever response (if present)

The onset of analgesia typically occurs within 30 minutes after an oral dose, with peak plasma concentrations reached in about 1 hour. The analgesic effect lasts 4-6 hours, making it suitable for intermittent dosing in acute pain episodes.

Conditions Treated with Ketorolac

Ketorolac is approved in Hong Kong for the short-term treatment of moderate to severe acute pain when an opioid is not required or when opioid therapy is being avoided. Common clinical scenarios include:

• Post-operative pain (up to 5 days after surgery)
• Pain from musculoskeletal injuries (e.g., sprains, fractures)
• Severe dental pain following extractions or oral surgery

Ketorolac is not indicated for chronic pain conditions such as arthritis, low back pain, or neuropathic pain, because prolonged NSAID use increases the risk of gastrointestinal, renal, and cardiovascular complications.

Who Should Not Use Ketorolac?

Absolute Contraindications

• Known hypersensitivity to Ketorolac, any other NSAID, or the trometamol salt
• Active peptic ulcer disease or a history of gastrointestinal bleeding
• Severe renal impairment (e.g., creatinine clearance < 30 mL/min)
• Established coronary artery disease, cerebrovascular disease, or peripheral arterial disease where NSAID use is contraindicated
• Use during the third trimester of pregnancy (risk of premature closure of the fetal ductus arteriosus)

Relative Contraindications

• Moderate renal or hepatic dysfunction - dose adjustment and careful monitoring required
• Elderly patients - higher susceptibility to renal and gastrointestinal adverse events
• Concurrent use of anticoagulants (e.g., warfarin, direct-acting oral anticoagulants) - increased bleeding risk
• History of asthma exacerbated by NSAIDs or aspirin-intolerant asthma

Special Populations

• Pregnancy: Avoid in the third trimester; use only if benefits outweigh risks in the first two trimesters.
• Breastfeeding: Small amounts are excreted in breast milk; consider alternative analgesics unless the infant is monitored.
• Pediatrics: Not approved for children under 16 years for oral administration.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal: Dyspepsia, nausea, abdominal discomfort (commonly reported)
• Central nervous system: Dizziness, headache, mild somnolence
• Renal: Transient increase in serum creatinine, especially in patients with baseline renal impairment

Serious Adverse Events

• Gastrointestinal bleeding or perforation: May present as black stools, vomiting blood, or severe abdominal pain; requires emergency care
• Renal failure: Oliguria, sudden weight gain, swelling; monitor urine output in at-risk patients
• Cardiovascular events: Hypertension, myocardial infarction, or stroke, particularly with high-dose or prolonged use

Drug Interactions

• Major: Concurrent anticoagulants (e.g., warfarin), antiplatelet agents (e.g., clopidogrel), and selective serotonin reuptake inhibitors (SSRIs) can synergistically increase bleeding risk.
• Moderate: Lithium, methotrexate, and certain antihypertensives (e.g., ACE inhibitors, diuretics) may require dose adjustments or enhanced monitoring.
• CYP interaction: Ketorolac is not a significant CYP substrate, but drugs that alter renal prostaglandin synthesis can affect its clearance.

Food and Lifestyle Interactions

• Food: Take Ketorolac with food or a full glass of water to lessen gastric irritation.
• Alcohol: Limit alcohol intake, as combined use heightens gastrointestinal bleeding risk.
• Driving: No specific impairment, but dizziness may affect some individuals; use caution if feeling unsteady.

Note: Patients should inform their healthcare provider of all prescription drugs, over-the-counter medications, herbal supplements, and dietary habits before starting Ketorolac.

How to Take Ketorolac

• Standard dosing: One 10 mg tablet orally every 4-6 hours as needed for pain.
• Maximum duration: Do not exceed 5 days of total therapy, including any parenteral (intramuscular or intravenous) dosing.
• Renal adjustment: For patients with moderate renal impairment, dosing may be reduced to 5 mg every 6-8 hours, not exceeding 20 mg per day, and treatment duration should be shortened.
• Missed dose: If a scheduled dose is missed and the next dosing interval is soon, skip the missed dose. Do not double-dose.
• Overdose: Symptoms may include severe stomach pain, nausea, vomiting, black stools, or decreased urine output. Seek emergency medical care; activated charcoal and supportive measures are the mainstays of treatment.
• Discontinuation: No taper is required for short-term use. Stopping abruptly is safe, but patients should be monitored for rebound pain.

Monitoring and Follow-Up

• Baseline labs: Prior to initiating therapy, assess renal function (serum creatinine, eGFR) and liver enzymes in patients with known hepatic disease.
• During therapy: Re-evaluate pain control, gastrointestinal tolerance, and signs of bleeding at each follow-up visit (typically every 2-3 days for short courses).
• When to seek care: Immediate medical attention is warranted for signs of gastrointestinal bleeding, sudden swelling, shortness of breath, or severe headache.

Storage and Handling

• Store tablets at room temperature (15-30 °C), protected from moisture, heat, and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets beyond the printed expiration date; discard according to local pharmacy guidelines.

Medication-Specific Glossary

Cyclooxygenase (COX)

An enzyme family (COX-1 and COX-2) that converts arachidonic acid into prostaglandins, key mediators of pain and inflammation.

Prostaglandin

Lipid compounds that sensitize nerve endings, promote inflammation, and regulate fever; reduced by NSAIDs to achieve analgesia.

Renal Clearance

The volume of plasma cleared of a drug by the kidneys per unit time; important for dosing adjustments in impaired kidney function.

Medical Disclaimer

This article provides educational information about Ketorolac and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.